Health Equity Impact Evaluation of New Treatments – Evidence Synthesis Methods to Overcome Data Gaps

Author(s):  
Jeroen P Jansen

Abstract Background: Distributional cost-effectiveness analysis (DCEA) has been introduced as an extension of conventional cost-effectiveness analysis to quantify health equity impacts. Although health disparities are recognized as an important concern, the typical analyses conducted to inform health technology assessment of a new intervention do not include a formal health equity impact evaluation or DCEA. One of the reasons is that the clinical trials for new interventions frequently do not have the power or are not designed to estimate the required treatment effects for sub-populations across which you want to analyze equity. The objective of the paper is to discuss how gaps in evidence regarding equity-relevant subgroup effects for new and existing interventions can potentially be overcome with advanced Bayesian evidence synthesis methods to facilitate a credible model-based DCEA. Methods: First, the evidence needs and challenges for a model-based DCEA are outlined. Next, alternative evidence synthesis methods will be summarized, followed by an illustrative example of implementing these methods. The paper will conclude with some practical recommendations. Results: The key evidence challenges for a DCEA relate to estimating relative treatment effects due to lack of inclusion of relevant subgroups in the randomized controlled trials (RCTs), lack of access to individual patient data (IPD) for all trials, small subgroups resulting in uncertain effects, and reporting gaps. Advanced Bayesian evidence synthesis methods can help overcome evidence gaps by considering all relevant direct, indirect, and external evidence simultaneously. Methods discussed include (network) meta-analysis with shrinkage estimation, conventional (network) meta-regression analysis, multi-level (network) meta-regression analysis, and generalized evidence synthesis. For a new intervention for which only RCT evidence is available and no real-world data, estimates can be improved if the assumption of exchangeable subgroup effects or the shared or exchangeable effect-modifier assumption among competing interventions can be defended. Furthermore, formal expert elicitation is worthwhile to improve estimates. Conclusion: This paper provides an overview of advanced evidence synthesis methods that may help overcome typical gaps in the evidence base to perform model-based DCEA along with some practical recommendations. Future simulation studies are needed to assess the pros and cons of different methods for different data gap scenarios.

2021 ◽  
Author(s):  
Jeroen P Jansen

Abstract Distributional cost-effectiveness analysis (DCEA) is an extension of conventional cost-effectiveness analysis to quantify health equity impacts. Although health disparities are recognized as an important concern, the typical analyses conducted to inform health technology assessment of a new intervention do not include a DCEA. One of the reasons brought forward is the relative sparseness of the available evidence for a new intervention. The objective of this paper is to review advanced evidence synthesis methods to estimate subgroup specific treatment effects relevant for a DCEA of new interventions. The paper will outline the evidence needs and gaps, present alternative evidence synthesis methods followed by an illustrative example, and conclude with some practical recommendations. Evidence challenges for estimating relative treatment effects are due to lack of inclusion of relevant subgroups in the randomized controlled trials (RCTs), lack of access to individual patient data, small subgroups resulting in uncertain effects, and reporting gaps. Evidence synthesis methods can help overcome evidence gaps by considering all relevant direct, indirect, and external evidence simultaneously. Methods of potential relevance include (network) meta-analysis with shrinkage estimation, conventional (network) meta-regression analysis, multi-level (network) meta-regression analysis, and generalized evidence synthesis. For a new intervention for which only RCT evidence is available and no real-world data, estimates can be improved if the assumption of exchangeable subgroup effects or the shared or exchangeable effect-modifier assumption among competing interventions can be defended. Future research is needed to assess the pros and cons of different methods for different data gap scenarios.


2021 ◽  
Author(s):  
Jeroen P Jansen

Abstract Distributional cost-effectiveness analysis (DCEA) is an extension of conventional cost-effectiveness analysis to quantify health equity impacts. Although health disparities are recognized as an important concern, the typical analyses conducted to inform health technology assessment of a new intervention do not include a DCEA. One of the reasons brought forward is the relative sparseness of the available evidence for a new intervention. The objective of this paper is to review advanced evidence synthesis methods to estimate subgroup specific treatment effects relevant for a DCEA of new interventions. The paper will outline the evidence needs and gaps, present alternative evidence synthesis methods followed by an illustrative example, and conclude with some practical recommendations. Evidence challenges for estimating relative treatment effects are due to lack of inclusion of relevant subgroups in the randomized controlled trials (RCTs), lack of access to individual patient data, small subgroups resulting in uncertain effects, and reporting gaps. Evidence synthesis methods can help overcome evidence gaps by considering all relevant direct, indirect, and external evidence simultaneously. Methods of potential relevance include (network) meta-analysis with shrinkage estimation, conventional (network) meta-regression analysis, multi-level (network) meta-regression analysis, and generalized evidence synthesis. For a new intervention for which only RCT evidence is available and no real-world data, estimates can be improved if the assumption of exchangeable subgroup effects or the shared or exchangeable effect-modifier assumption among competing interventions can be defended. Future research is needed to assess the pros and cons of different methods for different data gap scenarios.


2019 ◽  
Author(s):  
Melanie Chitwood ◽  
Daniele M. Pelissari ◽  
Gabriela Drummond Marques da Silva ◽  
Patricia Bartholomay ◽  
Marli Souza Rocha ◽  
...  

BMJ ◽  
2015 ◽  
Vol 350 (may12 7) ◽  
pp. h2016-h2016 ◽  
Author(s):  
J. A. Bogaards ◽  
J. Wallinga ◽  
R. H. Brakenhoff ◽  
C. J. L. M. Meijer ◽  
J. Berkhof

2016 ◽  
Vol 27 (7) ◽  
pp. 1043-1046 ◽  
Author(s):  
Benjamin Scheibehenne ◽  
Tahira Jamil ◽  
Eric-Jan Wagenmakers

2013 ◽  
Vol 142 (5) ◽  
pp. 964-974 ◽  
Author(s):  
M. SHUBIN ◽  
M. VIRTANEN ◽  
S. TOIKKANEN ◽  
O. LYYTIKÄINEN ◽  
K. AURANEN

SUMMARYIn Finland, the pandemic influenza virus A(H1N1)pdm09 was the dominant influenza strain during the pandemic season in 2009/2010 and presented alongside other influenza types during the 2010/2011 season. The true number of infected individuals is unknown, as surveillance missed a large portion of mild infections. We applied Bayesian evidence synthesis, combining available data from the national infectious disease registry with an ascertainment model and prior information on A(H1N1)pdm09 influenza and the surveillance system, to estimate the total incidence and hospitalization rate of A(H1N1)pdm09 infection. The estimated numbers of A(H1N1)pdm09 infections in Finland were 211 000 (4% of the population) in the 2009/2010 pandemic season and 53 000 (1% of the population) during the 2010/2011 season. Altogether, 1·1% of infected individuals were hospitalized. Only 1 infection per 25 was ascertained.


Sign in / Sign up

Export Citation Format

Share Document